Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsagaff, Mochamad Yusuf, Mulia, Eka Prasetya Budi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550882/
https://www.ncbi.nlm.nih.gov/pubmed/34717930
http://dx.doi.org/10.1016/j.ihj.2021.10.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550882/
https://www.ncbi.nlm.nih.gov/pubmed/34717930
http://dx.doi.org/10.1016/j.ihj.2021.10.011

Ejemplares similares